Portal de Periódicos da CAPES

Malignancies in hepatitis C virus‐positive and ‐negative kidney transplant recipients: A case‐controlled study

2017; Wiley; Volume: 19; Issue: 4 Linguagem: Inglês

10.1111/tid.12725

1399-3062

Gaëlle Dörr, Arnaud Del Bello, Florence Abravanel, Olivier Marion, Olivier Cointault, David Ribes, Laurence Lavayssière, Laure Esposito, Marie Béatrice Nogier, Anne Laure Hébral, Karine Sauné, Jacques Izopet, Nassim Kamar,

Hepatitis C virus research

Malignancies and lymphoma are common complications after kidney transplantation. However, no link has been made between the incidence of malignancies and hepatitis C virus (HCV) infection in this setting. This case-controlled study compared the incidence of malignancies, including lymphoma, between kidney transplant (KT) patients with or without HCV replication.A total of 99 HCV-positive RNA-positive KT patients were matched with 198 (1:2) anti-HCV-negative patients according to age, gender, and date of transplantation, and were followed for 145.8±78.4 months.During the follow-up period, 28 HCV-positive (28%) cases developed at least one cancer, and 64 (32%) patients developed cancer in the HCV-negative group (P=not significant [ns]). Survival without a cancer was similar between both groups. Thirteen HCV-positive patients (13%) developed at least one solid cancer vs 29 (15%) HCV-negative patients (P=ns). Survival without a solid cancer was similar between both groups. Three patients from the HCV-positive and 4 from the HCV-negative group developed a lymphoma. Only 2 patients from the HCV group died from hepatocellular carcinoma. Survival without a skin cancer was similar between both groups. Patient and death-censored graft survival rates were significantly lower in the HCV group.The incidences and types of malignancies were similar in the HCV-positive and HCV-negative KT patients.